Diphenylether

Diphenylether

SCHEMBL55934

C=C(C)C(=O)O.OCCO.c1ccc(Oc2ccccc2)cc1

nearest known ligand 0.47

Full drug profile on Sugi Atlas →

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LTA4H P09960 4/20 0.47
TSHR P16473 1/20 0.46
ERCC5 P28715 2/20 0.46
FEN1 P39748 2/20 0.46
SMN1; SMN2 Q16637 2/20 0.45
FFAR1 O14842 1/20 0.44
PARP10 Q53GL7 1/20 0.44
SRD5A2 P31213 2/20 0.43
HPGD P15428 2/20 0.43
PAX8 Q06710 1/20 0.43
MMP2 P08253 1/20 0.43
MMP9 P14780 1/20 0.43
AKR1C3 P42330 1/20 0.43
NPC1 O15118 1/20 0.42
CRHBP P24387 1/20 0.42
RAB9A P51151 1/20 0.42
CRHR2 Q13324 1/20 0.42
NR1H2 P55055 1/20 0.42
BAX Q07812 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Diphenylether SCHEMBL28722487 0.93 SMN1; SMN2 (0.43) LTA4HTSHRERCC5FEN1SMN1; SMN2
Diphenylether SCHEMBL1684012 0.92 LTA4H (0.55) LTA4HTSHRERCC5FEN1SMN1; SMN2
Diphenylether SCHEMBL20379696 0.89 PARP10 (0.50) LTA4HTSHRSMN1; SMN2FFAR1PARP10
Diphenylether SCHEMBL896890 0.88 LTA4H (0.55) LTA4HTSHRERCC5FEN1SMN1; SMN2
Diphenylether SCHEMBL5819753 0.85 LTA4H (0.46) LTA4HTSHRERCC5FEN1SMN1; SMN2
Biphenyl SCHEMBL28832981 0.82 SMN1; SMN2 (0.48) TSHRERCC5FEN1SMN1; SMN2FFAR1
Diphenylether SCHEMBL3428115 0.81 LTA4H (0.44) LTA4HTSHRERCC5FEN1SMN1; SMN2
Phenoxyethanol SCHEMBL8425236 0.81 ALDH1A1 (0.68) SMN1; SMN2PARP10RAB9A
Diphenylether SCHEMBL8065399 0.81 POLB (0.48) LTA4HTSHRSMN1; SMN2FFAR1PARP10
Diphenylether SCHEMBL4623522 0.81 LTA4H (0.63) LTA4HTSHRFFAR1PARP10SRD5A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 670 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260042870-A1 BINDER COMPOSITIONS AND USES THEREOF KNAUF INSULATION SPRL (BE) 2026-02-12 US claimed
EP-3247328-B1 METHODS, COMPOSITIONS, AND SYSTEMS FOR DELIVERING THERAPEUTIC AND DIAGNOSTIC AGENTS INTO CELLS GENEVANT SCIENCES GMBH (CH) 2026-01-07 EP claimed
WO-2025198684-A9 BaTiO3 NANOCRYSTALS AND NANOCOMPOSITES PIXELLIGENT TECHNOLOGIES LLC (US) 2025-11-27 WO claimed
US-12466899-B2 Binder compositions and uses thereof KNAUF INSULATION SPRL (BE) 2025-11-11 US claimed
US-20250230334-A1 SOLVENT-FREE FORMULATIONS AND NANOCOMPOSITES PT SPE SUBCO LLC (US) 2025-07-17 US claimed
US-20250198980-A1 COMBINATORIAL HIGH-THROUGHPUT SCREENING OF COMPLEX POLYMERIC ENZYME IMMOBILIZATION SUPPORTS THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) 2025-06-19 US claimed
CN-119978218-A Multi-stimulus response type photon film display material, preparation method and application thereof 中国科学院宁波材料技术与工程研究所 2025-05-13 CN claimed
US-12286549-B2 Solvent-free formulations and nanocomposites PT SPE SUBCO LLC (US) 2025-04-29 US claimed
CN-115066288-B Method for coupling ligands to composite materials 默克密理博有限公司 2025-03-11 CN claimed
CN-118853041-A Preparation method and product of lithium ion energy storage battery negative electrode SBR binder 苏州德比电子材料科技有限公司 2024-10-29 CN claimed
US-20130021554-A1 LIQUID CRYSTAL DISPLAY DEVICE INCLUDING SIDE SUPPORTING MEANS AND METHOD OF FABRICATING THE SAME LG DISPLAY CO., LTD (KR) 2013-01-24 US claimed
WO-2012037101-A2 CHROMATOGRAPHY MEMBRANES FOR THE PURIFICATION OF CHIRAL COMPOUNDS NATRIX SEPARATIONS INC. (CA) 2012-03-22 WO claimed
US-20120064601-A1 Chromatography Membranes for the Purification of Chiral Compounds NATRIX SEPARATIONS INC. (CA) 2012-03-15 US claimed
WO-2008106323-A2 A HIGH THROUGHPUT SCREENING METHOD AND APPARATUS TO PRODUCE MODIFIED POLYMERS PARTICULARLY MEMBRANES RENSSELAER POLYTECHNIC INSTITUTE (US) 2008-09-04 WO claimed
US-7297727-B2 Triarylsilyl(meth)acryloyl-containing polymers for marine coating compositions ARKEMA INC. (US) 2007-11-20 US claimed
EP-1479737-B1 Triarylsilyl(meth)acryloyl-containing polymers for marine coating compositions ARKEMA INC (US) 2006-08-16 EP claimed
EP-1479737-A1 Triarylsilyl(meth)acryloyl-containing polymers for marine coating compositions Atofina Chemicals, Inc. (US) 2004-11-24 EP claimed
US-20040138332-A1 Triarylsilyl(meth)acryloyl-containing polymers for marine coating compositions ARKEMA INC. 2004-07-15 US claimed
US-20030225184-A1 Triarylsilyl(meth)acryloyl-containing polymers for marine coating compositions ARKEMA INC. 2003-12-04 US claimed
EP-1367100-A1 Triarylsilyl (meth) acryloyl-containing polymers for marine coating compositions ATOFINA CHEMICALS, INC. (US) 2003-12-03 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260042870-A1 BINDER COMPOSITIONS AND USES THEREOF SMCHD1, VCL, FGB LTA4H 2865/4885TSHR 4450/4885ERCC5 405/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.